Oxford University vaccine shows around 70% protection


The coronavirus vaccine developed by the University of Oxford stops 70% of people developing Covid symptoms, a large-scale trial shows.It will be seen as a triumph, but also comes off the back of Pfizer and Moderna showing 95% protection.However, the Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two.So it will play a significant role in tackling the pandemic, if it is approved by regulators.There is also intriguing data that suggests perfecting the dose could increase protection up to 90.

Oxford Covid-19 vaccine shows 70% efficacy in phase 2/3 trialsSince the results are based on an interim data analysis, the company has said it will be conducting additional analysis based on further data to refine the efficacy reading and establish the duration of protectionOxford University’s AstraZeneca vaccine candidate, AZD1222, against coronavirus disease (Covid-19) has shown 70% efficacy on average, according to the newly published data of phase 2/3 clinical trials held in the United Kingdom and Brazil, the company announced on Monday.

In effect, the results mean that of all the people who get vaccinated, about 70% will not be infected by the disease.Also, experts had tried two different dosing regimens, of which one showed a better profile—close to 90% efficacy.“Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing Covid-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine,” said AstraZeneca in a statement issued on Monday.

“One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%,” the statement read.


Positive news for developing countries if they can master the dosing regime to get higher protection percentage.

6 Dimers
  • Sort By

This is very good, the analysis by Pfizer and Moderna is flawed as the sample size is very small.
And 70% is very good. Moderna and Pfizer will fall down to similar levels as sample size increases.